Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Compass Pathways on ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...

Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depression (TRD) ...

U.S. antitrust enforcers should consider blocking a bid by Compass, the nation’s largest residential real estate broker, to acquire rival Anywhere Real Estate, amid a housing shortage, two Democratic ...

Larger than the Jeep Renegade but smaller than the Cherokee, the Compass is sized to fit between the subcompact and compact SUV segments. The current second-generation Compass was introduced for the ...

Jeep adds Uconnect handsfree and satellite radio as standard equipment and the Latitude trim receives automatic headlights as standard. The Sport SE package and a Mojave Sand exterior color were also ...

The American Depositary Shares ("ADS") of the United Kingdom-based biotech Compass Pathways plc (CMPS) are soaring today, after management announced its psychedelic drug candidate COMP006 had met the ...

Compass, Inc. engages in the provision of an online real estate platform. Its platform provides an integrated suite of software for customer relationship management, marketing, client service, ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A psychedelic medicine for hard-to-treat depression ...

Kanen bought 1,573,950 Compass shares; estimated trade size $14.36 million based on quarterly average price. Quarter-end Compass position value rose by $29.11 million, reflecting both trading and ...